Last reviewed · How we verify
NCT07231250
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Phase 2 trial testing Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone in DLBCL - Diffuse Large B Cell Lymphoma in 40 participants. Not yet recruiting.
15 September 2026
Quick facts
| Lead sponsor | Li Zhiming |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 15 January 2026 |
| Primary completion | 15 September 2026 |
| Estimated completion | 15 September 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone — full drug profile →
Conditions studied
- DLBCL - Diffuse Large B Cell Lymphoma — all drugs for DLBCL - Diffuse Large B Cell Lymphoma →
- Chemo-free Therapy — all drugs for Chemo-free Therapy →
- Bispecific Antibody — all drugs for Bispecific Antibody →
Sponsor
Li Zhiming — full company profile →
Who can join
18 and older, any sex, with DLBCL - Diffuse Large B Cell Lymphoma or Chemo-free Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-center, phase II, prospective study. The main purpose of study is to evaluate the efficacy and safety of Glofitamab plus Polatuzumab vedotin and Zuberitamab in patients with newly diagnosed diffuse large B-cell lymphoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.
Maher N, Al Deeban B, Diop NM, Assaf J, et al · · 2026 · PMID 42121895 · DOI 10.3390/cells15090794
Verify or expand the search:
- PubMed search for NCT07231250
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for DLBCL - Diffuse Large B Cell Lymphoma
Currently open trials in the same condition.
- NCT07288879 — DALY II Japan/MB-CART2019.1 for DLBCL · Phase 2 · recruiting
- NCT07255963 — Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL · Phase 2 · recruiting
- NCT06846463 — Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ · Phase 2 · recruiting
- NCT06736613 — A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · Phase 2 · recruiting
- NCT06891157 — Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes · Phase 2 · recruiting
Other Li Zhiming trials
Trials by the same sponsor.
- NCT06890585 — Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor · Phase 2 · not yet recruiting
- NCT06985472 — Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL · Phase 2 · recruiting
- NCT05422066 — Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07231250 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Li Zhiming
- Last refreshed: 19 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07231250.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing